Clinical Trials
25
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Completed
19
76.0%
Recruiting
1
4.0%
Terminated
4
16.0%
Withdrawn
1
4.0%
No approval data available
- Valerio Therapeutics signed a binding offer to acquire Etherna Immunotherapies for a total enterprise value of €30 million, combining complementary RNA platform technologies. - The merger pairs Valerio's single-domain antibody targeting and conjugation technologies with Etherna's mRNA and customizable lipid nanoparticle (cLNP) capabilities plus GMP manufacturing. - The combined entity aims to advance at least two immunological programs through IND-enabling studies and into the clinic within 18 to 24 months, led by an in vivo CAR-T approach targeting pathological B- and T-cells. - The transaction is supported by existing Valerio shareholders with secured financing and voting commitments representing over 70% of voting rights, with a six-week exclusivity period to finalize documentation.
- Valerio Therapeutics announces immediate discontinuation of all clinical trials, including the VIO-01 trial, amid financial challenges with only three months of cash runway remaining. - The company will shut down its U.S. operations in Lexington, MA and cease clinical-stage oncology programs to focus exclusively on early-stage drug development platform technologies. - Strategic restructuring will emphasize development of single chain antibody platform integrated with chemistry capabilities and oligonucleotides expertise for future therapeutic development.
- Valerio Therapeutics has acquired Emglev Therapeutics, gaining access to innovative single-domain antibody (sdAb) technology that enables fully human antibody development through in vitro processes. - The acquisition, executed through Valerio's subsidiary Valour Bio, strengthens their therapeutic pipeline with applications in autoimmune diseases, inflammatory disorders, and cancer treatment modalities. - Emglev's platform has demonstrated preclinical success with various therapeutic approaches, including CAR-T sdAb, BiTE sdAb, and sdAb-drug conjugates, promising accelerated development with reduced immunogenicity risks.
